Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Update in Antifungal Therapy of Dermatophytosis

Update in Antifungal Therapy of Dermatophytosis Treatment of dermatophyte infection involves primarily oral and/or topical formulations of azoles or allylamines, particularly itraconazole and terbinafine. Topical medications applied once or twice daily are the primary treatment indicated for tinea corporis/cruris, and tinea pedis/manuum. Use of oral antifungals may be practical where the tinea involvement is extensive or chronic, or where application of a topical is not feasible. For tinea unguium (onychomycosis) and tinea capitis, oral therapies are the primary treatments provided. Recently, topical amorolfine and ciclopirox formulations have been approved for use in milder onychomycosis cases, and their role in the treatment of the different clinical forms of onychomycosis is currently being defined. Relapse of infection remains a problem, particularly with tinea pedis/unguium. Appropriate follow-up duration and education of patients on proper foot hygiene are also important components in providing effective therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Mycopathologia Springer Journals

Update in Antifungal Therapy of Dermatophytosis

Mycopathologia , Volume 166 (6) – May 14, 2008

Loading next page...
 
/lp/springer-journal/update-in-antifungal-therapy-of-dermatophytosis-Tx0w9VDSXq

References (71)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer Science+Business Media B.V.
Subject
Life Sciences; Microbial Ecology; Plant Sciences ; Medical Microbiology ; Microbiology
ISSN
0301-486X
eISSN
1573-0832
DOI
10.1007/s11046-008-9109-0
pmid
18478357
Publisher site
See Article on Publisher Site

Abstract

Treatment of dermatophyte infection involves primarily oral and/or topical formulations of azoles or allylamines, particularly itraconazole and terbinafine. Topical medications applied once or twice daily are the primary treatment indicated for tinea corporis/cruris, and tinea pedis/manuum. Use of oral antifungals may be practical where the tinea involvement is extensive or chronic, or where application of a topical is not feasible. For tinea unguium (onychomycosis) and tinea capitis, oral therapies are the primary treatments provided. Recently, topical amorolfine and ciclopirox formulations have been approved for use in milder onychomycosis cases, and their role in the treatment of the different clinical forms of onychomycosis is currently being defined. Relapse of infection remains a problem, particularly with tinea pedis/unguium. Appropriate follow-up duration and education of patients on proper foot hygiene are also important components in providing effective therapy.

Journal

MycopathologiaSpringer Journals

Published: May 14, 2008

There are no references for this article.